

Special Issue

Strategies and Challenges for the Next Generation of Antibody Drug Conjugates

Message from the Guest Editor

Dear Colleagues: Antibody-drug conjugates (ADCs) are designed to selectively deliver a cytotoxic payload to the cancer cell. There are now seven approved ADCs for the treatment of several different cancers and ~80 ADCs in clinical development with over 600 clinical trials, which highlights the exponential growth for this important therapeutic landscape. Past 10 years, ADC field has been witnessing significant technology improvements with respect to ADC target selection, payload diversity, linker design, site-specific conjugation technology and application of clinical and translational strategies in developing next generation ADCs. In this special issue, we like to highlight many such pre-clinical, translational and clinical findings to improve therapeutic index of this novel ADC therapeutic platform, thus by making paradigm shift in cancer chemotherapy.

Guest Editor

Dr. Jagath Reddy Junutula

Research & Development, ModMab Therapeutics, Inc., Foster City, CA, USA

Deadline for manuscript submissions

closed (15 July 2021)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/39740

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).